BRAF

February 24, 2022

Melanoma treatment response

Targeting the interaction between melanoma and immune cells could improve responses to targeted cancer therapies, Vanderbilt researchers found.

By Sarah E. Glass
April 11, 2018

“Idling” cancer cells may return

Vanderbilt investigators have discovered that cancer treatment induces an “idling” state for cells, which could promote resistance to treatment.

By Bill Snyder
June 14, 2017

PET imaging to predict tumor response

A PET probe that detects the amino acid glutamine predicts whether tumors respond to certain targeted therapies in preclinical animal models.

By Leigh MacMillan
October 29, 2015

Investigators find clues to melanoma treatment resistance

Nearly half of all patients with malignant melanoma, the most deadly form of skin cancer, have a mutation in the BRAF gene found in their tumors. Mutations in the BRAF gene turn on a cancer growth switch known as the MAP kinase pathway.

By VUMC News and Communications
October 25, 2012

Combined drug therapy may delay melanoma progression

Combination therapy with two drugs delayed the development of treatment resistance in patients with metastatic melanoma that expresses a specific mutation in the BRAF gene.

By VUMC News and Communications
July 26, 2012

Study finds mutation in melanoma sensitive to drug

An uncommon mutation of the BRAF gene in melanoma patients has been found to respond to a specific drug therapy, providing a rationale for routine screening and therapy in melanoma patients who harbor the BRAF L597 mutation.

By VUMC News and Communications
April 26, 2012

New drug mutes more melanomas

An experimental melanoma drug may be beneficial for patients not eligible for targeted therapies.
By VUMC News and Communications